Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections
The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
Purpose: To identify the visual acuity outcomes of patients with age-related macular degeneration treated with intravitreal anti–vascular endothelial growth factor injections over a 10-year period. Methods: This was a retrospective, cohort study of eyes with exudative age-related macular degeneration that received ≥2 intravitreal anti–vascular endothelial growth factor injections and had at least 10 years of follow-up after the initiation of treatment. Snellen visual acuity was recorded at baseline and then annually until the last year of follow-up. Optical coherence tomography data were collected at the time of treatment initiation and at the last examination visit. A subanalysis was performed on patients who continued to receive anti–vascular endothelial growth factor therapy using a modified treat and extend protocol versus those who discontinued treatment for longer than 1 year. Results: One hundred thirty eyes of 115 patients met the inclusion criteria. The mean follow-up after treatment initiation was 11.1 ± 0.7 years. Eyes received an average of 45.1 ± 32.3 intravitreal injections in total and a mean of 5 to 7 injections per year. The baseline mean logMAR visual acuity was 0.61 ± 0.5 (Snellen acuity 20/81), and the final mean logMAR visual acuity was 0.88 ± 0.7 (20/152, P value = <0.0001). There were 40 eyes that received at least one injection every year. These eyes did not have a significant change in visual acuity between the baseline and final examinations 0.47 ± 0.4 (20/59 vs. 0.58 ± 0.5 [20/76, P = 0.28]), whereas the eyes that did not receive at least one injection every year saw a significant decline in visual acuity 0.67 ± 0.5 (20/94 vs. 1.01 ± 0.7 [20/205, P < 0.0001]). Conclusion: Eyes with exudative age-related macular degeneration that received intravitreal injections every year had stable visual acuity over a 10-year period. Continuous intravitreal anti–vascular endothelial growth factor therapy may stabilize visual acuity for 10 years and potentially longer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is in direct contrast to current treatment paradigms where a decrease in the number of bolus anti-VEGF intravitreal injections results in potentially irreversible worsening of BCVA and OCT parameters.14,25,26”
In the citing paper
“Although the eye is a relatively immune privileged organ, inflammation has nonetheless been a potentially limiting factor in ocular gene therapy.26, 27, 28, 29”
In the citing paper
“Although the eye is a relatively immune privileged organ, inflammation has nonetheless been a potentially limiting factor in ocular gene therapy.26, 27, 28, 29”
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023
(2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00967-9 · Cited by 814
Maguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Bressler, N. M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01237-5 · Cited by 666
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.015 · Cited by 590
Cited by
Khanani, A. M., Boyer, D. S., Wykoff, C. C., Regillo, C. D., Busbee, B. G., Pieramici, D., Danzig, C. J., Joondeph, B. C., Major, J. C., Turpcu, A., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102394 · Cited by 76
“14,25,26 29 Independent of the route of administration (subretinal, intravitreal, or suprachoroidal), a dose-dependent in fl ammatory reaction has been noted in nearly all ocular gene therapies.”
BackgroundFu, D. J., Keenan, T. D. L., Faes, L., Lim, E., Wagner, S. K., Moraes, G., Huemer, J. C., Kern, C., Patel, P. J., Balaskas, K., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.5044 · Cited by 43
Spooner, K., Fraser‐Bell, S., Hong, T., Phan, L. T., Wong, J., & Chang, A. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.09.019 · Cited by 18
Ten-year survival trends of neovascular age-related macular degeneration at first presentation
Arpa, C., Khalid, H., Chandra, S., Wagner, S. K., Fasler, K., Faes, L., Pooprasert, P., Chopra, R., Moraes, G., Balaskas, K., et al. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317161 · Cited by 18
Kaufmann, G. T., Boucher, N., Sharma, C., Aggarwal, N., & Starr, M. R. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.10.017 · Cited by 13
Self-citation
Metadata
- Authors
- Starr, M. R., Kung, F. F., Mejia, C. A., Bui, Y. T., & Bakri, S. J.
- Affiliations
- Mayo Clinic (US)
- Mayo Clinic Alix School of Medicine, Rochester, Minnesota.
- Corresponding author
- Starr, Matthew R.
- Bakri, Sophie J.
- Venue
- Retina
- Published
- 2019-11-13
- Volume
- 40
- Issue
- 9
- Pages
- 1665-1672
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2985629677
- Cited by
- 22
- References
- 33
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 6 · 2020: 5
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, intravitreal anti-VEGF injection, visual acuity outcomes, long-term follow-up, treat-and-extend protocol, treatment discontinuation, visual acuity stability, anti-VEGF therapy, optical coherence tomography, retinal pigment epithelium thickness, retinal thickness, retinal pigment epithelium
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Exudates and Transudates, Female, Follow-Up Studies, Humans, Male, Retrospective Studies, Visual Acuity, Treatment Outcome, Choroidal Neovascularization, Angiogenesis Inhibitors, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections. https://app.cochat.ai/papers/10.1097/iae.0000000000002668
- The paper
- Starr, M. R., Kung, F. F., Mejia, C. A., Bui, Y. T., & Bakri, S. J. (2020). Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections. Retina. https://doi.org/10.1097/iae.0000000000002668
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.